Sunday 18 October 2026
Export CABA’s income statement to Excel — free account
Cabaletta Bio, Inc.
CABA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 53.4% and free cash flow fell 35.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.41
0.14
−9.03%
Follow CABA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (93.20%) | (156.03%) | (126.98%) | (101.06%) |
+8 more TTM periods Free account |
|
| (75.36%) | (111.99%) | (95.88%) | (80.43%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(94.14%) | (212.91%) | (185.19%) | (131.13%) | |
Free Cash Flow per Share |
(1.02) | (1.28) | (1.66) | (1.18) | |
Free Cash Flow |
(153.93) | (142.84) | (132.31) | (120.26) | |
Capital Expenditures |
— | — | (1.23) | (1.40) | |
| Other line items | |||||
Cash ROIC |
(35.33%) | (64.94%) | (53.86%) | (40.17%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(80.94) | (76.47) | (85.95) | (44.54) | |
Operating CF/Net income |
0.85 | 0.81 | 0.78 | 0.75 | |
Depreciation/Fixed assets |
7.85 | 7.39 | 6.41 | 2.04 | |
Capex/Depreciation |
0.00 | 0.00 | (0.10) | (0.33) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.02) | (1.28) | (1.64) | (1.16) | |
Capex per Share |
0.00 | 0.00 | (0.02) | (0.01) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates